FDA rejects Santen’s intravitreal uveitis therapy

Shares in Santen Pharmaceutical (OTC:SNPHY) fell -3% today after the company’s U.S. subsidiary said that the FDA rejected the application for its intravitreal sirolimus therapy

The company is developing its DE-109 product to treat people with noninfectious uveitis of the posterior segment, which can cause blindness in adults.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA rejects Santen’s intravitreal uveitis therapy appeared first on MassDevice.

from MassDevice http://ift.tt/2BLQusV